Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2023.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Hologic reported after the close of the market Thursday that its non-COVID fiscal fourth quarter organic revenues grew 17 percent compared to one year earlier on a constant currency basis with double-digit organic growth across all its divisions.

ARUP Laboratories said Friday its companion diagnostic to help identify which patients are eligible for treatment with a gene therapy for hemophilia A received CE marking under the European Union's In Vitro Diagnostics Regulation (IVDR).

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2023, which include the consolidated financial results for GRAIL.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fourth quarter and full year of fiscal 2023, which ended September 30, 2023.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced results for the third quarter ended September 30, 2023.

Siemens Healthineers reported Wednesday that its non-COVID-19 revenues rose about 11 percent year over year on a comparable basis in its fiscal fourth quarter with strong growth in its Varian Medical Systems and imaging segments, along with low-single-digit growth in its diagnostics segment.

Danaher subsidiary Beckman Coulter Life Sciences and Pillar Biosciences announced an agreement on Tuesday to develop next-generation sequencing-based tests for cancer.

Roche announced on Tuesday that its Cobas HPV test has received approval from the US Food and Drug Administration for use on the Cobas 5800 instrument.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $628.3 million for the third quarter ended September 30, 2023, compared to $523.1 million for the same period of 2022.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Co-Diagnostics has received an $8.97m grant from the Bill & Melinda Gates Foundation to support a tuberculosis (TB) test that is under development.